Anti-β2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome

Blood

Volumn 102, Issue 8, 2003, Pages 2717-2723

  Galli, Monica ^a   Luciani, Davide ^b   Bertolini, Guido ^b   Barbui, Tiziano ^b  

^a OSPEDALI RIUNITI   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROTHROMBIN ANTIBODY;

ANALYTIC METHOD; ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; BLOOD CLOTTING TEST; CALCULATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; META ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; STANDARDIZATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; VEIN THROMBOSIS;

EID: 0141958839     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-11-3334     Document Type: Review

References (69)

1. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum. 1999;42:1309-1311.
2. Asherson RA, Khamashta MA, Ordi-Ros J, et al. The "primary" antiphospholipid syndrome; major clinical and serological features. Medicine (Baltimore). 1989;68:366-374.
3. Alarcon-Segovia D, Deleze M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L. Antiphospholipid antibodies and the antiphospholipid syndrome in SLE: a prospective analysis of 500 consecutive patients. Medicine. 1989;68:353-365.
4. Triplett DA, Boffa MC. Lupus anticoagulant: detection, standardization and heterogenity. In: Asherson RA, Cervera R, Piette J-C, Shoenfeld Y, eds. The Antiphospholipid Syndrome II: Autoimmune Thrombosis. Amsterdam, The Netherlands: Elsevier; 2002:23-28.
5. Pierangeli SS, Harris EN. Antibodies to cardiolipin and other phosholipids. In: Asherson RA, Cervera R, Piette J-C, Shoenfeld Y, eds. The Antiphospholipid Syndrome II: Autoimmune Thrombosis. Amsterdam, The Netherlands: Elsevier; 2002:29-43.
6. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost. 1995;74:1185-1190.
7. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors of thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101:1827-1832.
8. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990;87:4120-4124.
9. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 1990;334:1544-1547.
10. Matsuura E, Igarashi Y, Fujimoto M, et al. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet. 1990;336:177-178.
11. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost. 1991;66:629-632.
12. Arvieux J, Darnige L, Reber G, Bensa JC, Colomb MG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost. 1995;74:1120-1125.
13. Galli M, Beretta G, Daldossi M, Bevers EM, Barbui T. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost. 1997;77:486-491.
14. Oosting JD, Derksen RHWM, Bobbink IW, Hackeng TM, Bouma B, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood. 1993;81:2618-2625.
15. Matsuda J, Saitoh N, Gohchi K, Gotoh M, Tsukamoto M, Anti-annexin V antibody in systemic lupus erytheatosus patients with lupus anticoagulant and/ or anticardiolipin antibody. Am J Hematol. 1994;47:56-58.
16. Sugi T, McIntyre JA. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood. 1995;86:3083-3089.
17. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet. 1993;341:923-925.
18. Cugno M, Dominguez M, Cabibbe M, et al. Antibodies to tissue-type plasminogen activator in plasma from patients with primari antiphospholipid syndrome. Br J Haematol. 2000;108:871-875.
19. Jones DW, Gallimore MJ, Harris SL, Winter M. Antibodies to factor XII associated with lupus anticoagulant. Thromb Haemost. 1999;81:387-390.
20. Rampazzo P, Biasiolo A, Garin J, et al. Some patients with antiphospholipid syndrome express hitherto undescribed antibodies to cardiolipin-binding proteins. Thromb Haemost. 2001:85:57-62.
21. Bidot CJ, Jy W, Horstman LL, et al. Factor VII/ VIIa: a new antigen in the anti-phospholipid antibody syndrome. Br J Haematol. 2003;120:618-626.
22. Arnout J. Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants. Thromb Haemost. 2001;86:83-91.
23. De Groot PG, Bouma B, Lutters BCH, Derksen RHWM. β2-glycoprotein I and anti-β2-glycoprotein I antibodies. In: Asherson RA, Cervera R, Piette J-C, Shoenfeld Y, eds. The Antiphospholipid Syndrome II. Autoimmune Thrombosis. Amsterdam, The Netherlands: Elsevier; 2002:45-57.
24. Galli M, Barbui T. Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. Blood, 1999;93:2149-2157.
25. Galli, M, Bevers EM, Barbui T. Immunologic properties and anticoagulant activity of antiphospholipid antibodies. In: Levine SR, Brey RL, eds. Clinical Approach to Antiphospolipid Antibodies. Boston, MA: Butterworth; 2000:19-31.
26. Pasquier E, Amiral J, de Saint Martin L, Mottier D. A cross-sectional study of antiphospholipid-protein antibodies in patients with venous thromboembolism. Thromb Haemost. 2001;86:538-542.
27. Vaarala O, Puurunen M, Manttari M, Manninen V, Aho K, Palouso T. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost. 1996;75:456-459.
28. Palosuo T, Virtamo J, Haukka J, et al. High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men. Thromb Haemost. 1997;78:1178-1182.
29. Previtali S, Barbui T, Galli M. Antiβ2-glycoprotein I and anti-prothrombin antibodies in antiphospholipid-negative patients with thrombosis: a case-control study. Thromb Haemost. 2002:88:729-732.
30. Brey RL, Abbott RD, Curb JD, et al. β2-glycoprotein-I-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu heart program. Stroke. 2001;32:1701-1706.
31. Viard J-P, Amoura Z, Bach J-F. Association of anti-β2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med. 1992;93:181-186.
32. Balestrieri G, Tincani A, Spatola L, et al. Anti-β2-glycoprotein I antibodies: a marker of antiphospholipid syndrome? Lupus. 1995;4:122-130.
33. Cabiedes J, Cabral AR, Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythamatosus associate more strongly with anti-β2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol. 1995;22:1898-1906.
34. Cabral AR, Cabiedes J, Alarcon-Segovia D. Antibodies to phospholipid-free β2-glycoprotein-I in patients with primary antiphospholipid syndrome. J Rheumatol. 1995;22:1894-1898.
35. Martinuzzo ME, Forastiero RR, Carreras LO. Anti-β2 glycoprotein I antibodies: detection and association with thrombosis. Br J Haematol. 1995;89:397-402.
36. Amengual O, Atsumi T, Khamashta MA, Koike T, Hughes GRV. Specificity of ELISA for antibody to β2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol, 1996;35:1239-1245.
37. Roubey RAS, Maldonado MA, Byrd SN. Comparison of an enzyme-linked immunosorbent assay for antibodies to β2-glycoprotein I and a conventional anticardiolipin immunoassay. Arthritis Rheum. 1996;39:1606-1607.
38. Tsutsumi A, Matsuura E, Ichikawa K, et al. Antibodies to β2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum. 1996;39:1466-1474.
39. Sanmarco M, Soler C, Christides C, et al. Prevalence and clinical significance of IgG isotype anti-β2-glycoprotein I antibodies in antiphospholipid syndrome: a comparative study with anticardiolipin antibodies. J Lab Clin Med. 1997;129:499-506.
40. Day HM, Thiagarajan P, Ahn C, Reveille JD, Tinker KF, Arnett FC. Autoantibodies to β2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests. J Rheumatol. 1998;25:667-674.
41. Fanopoulos D, Teodorescu MR, Varga J, Teodorescu M. High frequency of abnormal levels of IgA anti-β2-glycoprotein I antibodies in patients with systemic lupus erythematosus: relationship with antiphospholipid syndrome. J Rheumatol. 1998;25:675-680.
42. Zanon E, Prandoni P, Vianello F, et al. Anti-β2-glycoprotein I antibodies in patients with acute venous thromboembolism: prevalence and association with recurrent thromboembolism. Thromb Res. 1999;96:269-274.
43. Bruce IN, Clark-Soloninka CA, Spitzer KA, Gladman DD, Urowitz MB, Laskin CA. Prevalence of antibodies to β2-glycoprotein I in systemic lupus erythematosus and their association with antiphospholipid antibody syndrome criteria: a single center study and literature review. J Rheumatol. 2000;27:2833-2837.
44. Lee S-S, Cho M-L, Joo Y-S, et al. Isotypes of anti-β2-glycoprotein I antibodies: association with thrombosis in patients with systemic lupus erythematosus. J Rheumatol. 2001;28:520-524.
45. Horbach DA, van Oort E, Donders CJM, Derksen RHWM, De Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus: comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost. 1996;76:916-924.
46. Pengo V, Biasiolo A, Brocco T, Tonetto S, Ruffatti A. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost. 1996; 75:721-724.
47. Puurunen M, Vaarala O, Julkunen H, Aho K, Palosuo T. Antibodies to phospholipid-binding plasma proteins and occurrence of thrombosis in patients with systemic lupus erythematosus. Clin Immunol Immunopathol. 1996;80:16-22.
48. Forastiero RR, Martinuzzo ME, Cerrato GS, Kordich LC, Carreras LO. Relationship of antiβ2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thromb Haemost. 1997;78:1008-1014.
49. Swadzba J, deClerck L, Stevens WJ, et al. Anticardiolipin, anti-β2-glycoprotein I, antiprothrombin antibodies, and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis. J Rheumatol. 1997;24:1710-1715.
50. Martinuzzo ME, Pombo G, Forastiero RR, Cerrato GS, Colorio CC, Carreras LO. Lupus anticoagulant, high levels of anticardiolipin, and anti-β2-glycoprotein I antibodies are associated with chronic thromboembolic pulmonary hypertension. J Rheumatol. 1998;25:1313-1319.
51. Atsumi T, Ieko M, Bertolaccini ML, et al. Association of autoantibodies against the phosphatidyl-serine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum. 2000;43:1982-1993.
52. Galli M, Dlott J, Norbis F, et al. Lupus anticoagulants and thrombosis: clinical association of different coagulation and immunologic tests. Thromb Haemost. 2000;84:1012-1016.
53. Lakos G, Kiss E, Regeczy N, et al. Antiprothrombin and antiannexin V antibodies imply risk of thrombosis in patients with systemic autoimmune diseases. J Rheumatol. 2000;27:924-929.
54. Nojima J, Kuratsune H, Suehisa E, et al. Anti-prothrombin antibodies combined with lupus anticoagulant activity is an essential risk factor for venous thromboembolism in patients with systemic Jupus erythematosus. Br J Haematol. 2001;114:647-654.
55. Bertolaccini ML, Atsumi T, Khamashta MA, Amengual O, Hughes GRV. Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus. J Rheumatol. 1998;25:1104-1108.
56. Munoz-Rodriguez F-J, Reverter J-C, Font J, et al. Prevalence and clinical significance of antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome. Haematologica. 2000;85:632-637.
57. Sorice M, Pittoni V, Circella A, et al. Antiprothrombin but not "pure" anti-cardiolipin antibodies are associated with the clinical features of the antiphospholipid antibody syndrome. Thromb Haemost. 1998;80:713-715.
58. Arvieux J, Darnige L, Caron C, Reber G, Bensa JC, Colomb MG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost. 1995;74:1120-1125.
59. Guerin J, Feighery C, Sim RB, Jackson J. Antibodies to β2-glycoprotein I: a specific marker for the antiphospholipid syndrome. Clin Exp Immunol. 1997;109:304-309.
60. Priori R, Conti F, Pittoni V, Garofalo T, Sorice M, Valesini G. Is there a role for anti-phospholipid-binding protein antibodies in the pathogenesis of thrombosis in Behcet's disease [letter]? Thromb Haemost. 2000;83:173.
61. Donohoe S, Mackie JI, Isenberg D, Machin SJ. Anti-prothrombin antibodies: assay conditions and clinical associations in the anti-phospholipid syndrome. Br J Haematol. 2001;113:544-549.
62. Felson DT. Bias in meta-analytical research. J Clin Epidemiol. 1992;8:885-892.
63. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000:283:2008-2012.
64. Colditz GA, Burdick E, Mosteller F. Heterogeneity in meta-analysis of data from epidemiologic studies: a commentary. Am Epidemiol. 1995;142:371-382.
65. Jni P, Witschi A, Bloch R, Egger M. The hazard of scoring the quality of clinical trials for meta-analysis. JAMA. 1999;282:1054-1060.
66. Vaarala O, Palosuo T, Kleemola M, Aho K. Anticardiolipin response in acute infection. Clin Immunol Innumopathol. 1986;41:8-15.
67. Santiago M, Martinelli R, Ko A, et al. Anti-beta2 glycoprotein I and anticardiolipin antibodies in leptospirosis, syphilis and Kala-azar. Clin Exp Rheumatol. 20;19:425-430.
68. Giordano P, Galli M, Del Vecchio G, et al. Lupus anticoagulant, anticardiolipin antibodies and hepatitis C virus infection in thalassemia. Br J Haematol. 1998;102:903-906.
69. Reber G, Schousboe I, Tincani A, et al. Inter-laboratory variability of anti-β2-glycoprotein I measurement: a collaborative study in the frame of the European Forum on antiphospholipid antibodies standardization group. Thromb Haemost. 2002;88:66-73.